Receives Tentative Approval for Olaparib Tablets - Natco Pharma Ltd

Code BSE: 524816 NSE: $NATCOPHARM NATCO receives Tentative Approval for Olaparib Tablets from the United States Food and Drug Administration (U.S. FDA) NATCO today received tentative approval from the U.S. FDA for Olaparib, 100 mg, and 150 mg, as bioequivalent to reference listed drug Lynparza tablets of AstraZeneca Pharmaceuticals for the indication in the approved labelling. NATCO will be manufacturing Olaparib tablets and our partner Alembic Pharmaceuticals Limited (Alembic), would be distributing the product in the U.S.